1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimen
1993
Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT).
Kacinaki B, Wilson L, Goodrich A, Edelson R, Heald P, Braverman I. Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 186-187. DOI: 10.1016/0360-3016(93)90727-d.Peer-Reviewed Original Research